Refractory Shock: Second-Line Agents When Norepinephrine Isn’t Enough

By The ICU Notebook — Updated 2026 · 10-minute clinical read

Defining Refractory Shock

Refractory septic shock has no single universally accepted definition, but in practice it means persistent hypotension (MAP <65 mmHg) despite adequate fluid resuscitation and norepinephrine doses exceeding 0.25–0.5 mcg/kg/min. Some centers add a second agent at 0.1 mcg/kg/min; others wait until 0.25. Know your unit protocol.

Mortality from refractory septic shock ranges from 50% to 80% depending on the population studied. Understanding which agents to reach for, in what order, and why each mechanism is different is core ICU nursing knowledge—you are at the bedside when the physician is managing three other patients.

Vasopressin: The Standard Second Agent

Vasopressin (antidiuretic hormone, ADH) acts through V1 receptors on vascular smooth muscle, causing vasoconstriction through a mechanism entirely independent of adrenergic receptors. This is why it remains effective when catecholamine receptors are downregulated from prolonged shock—a process called catecholamine desensitization that begins within hours of sustained adrenergic stimulation.

Dosing: Fixed at 0.03–0.04 units/min IV. Do not titrate vasopressin like norepinephrine. The VASST and VANISH trials both established 0.03 units/min as the standard dose. Going higher (0.1 units/min or above) causes coronary and mesenteric ischemia—the high-dose vasopressin studies that showed harm used doses 3x the current recommendation.

When to add it: Surviving Sepsis Campaign 2021 guidelines recommend adding vasopressin when norepinephrine reaches 0.25 mcg/kg/min, or to enable norepinephrine dose reduction. The VASST trial showed mortality benefit specifically in patients with less severe shock (norepinephrine <15 mcg/min). The benefit is smaller at higher catecholamine doses.

Key bedside monitoring:

• Skin ischemia: Vasopressin causes profound peripheral vasoconstriction. Check extremities, lips, and toes every 2 hours. Ischemic digits and toes are a recognized complication of prolonged vasopressin infusion, particularly in patients who are also on norepinephrine.
• Hyponatremia: Vasopressin also acts on V2 receptors, causing water retention. Follow sodium q4–6h in extended infusions, especially if the patient is receiving hypotonic fluids.
• Mesenteric ischemia: New abdominal distension, cessation of bowel sounds, rising lactate without another explanation, or bloody stool should raise concern for bowel ischemia.
• Coronary ischemia: New ECG changes or a rising troponin during vasopressin infusion warrants evaluation, especially in patients with existing coronary disease.

Epinephrine: When Cardiac Output Is Also Failing

Epinephrine combines alpha-1 (vasoconstriction) and beta-1 (positive inotropy and chronotropy) effects. It is the preferred add-on when the shock picture includes a cardiogenic component—poor cardiac output, low mixed venous O2 saturation (<65%), or clinical signs of forward failure: cold extremities, weak central pulses, mottling despite adequate filling pressures.

Dosing: 0.01–0.5 mcg/kg/min IV, titrated to MAP target. There is no fixed ceiling; titrate to effect and hemodynamic response.

The lactate problem with epinephrine: Epinephrine causes significant lactic acidosis through beta-2 receptor activation of skeletal muscle glycogenolysis—not tissue hypoxia. This is the epinephrine-lactate phenomenon. If lactate rises sharply after starting epinephrine but hemodynamics and urine output are improving, do not assume worsening shock. Trend the clinical picture alongside the lactate number.

Other epinephrine effects to monitor:

• Tachycardia: rates above 120–130 bpm reduce diastolic filling time and can worsen coronary perfusion in patients with ischemic heart disease
• Hyperglycemia: requires more aggressive insulin infusion management; expect glucose to rise 30–60 mg/dL within 1–2 hours of starting
• Arrhythmias: atrial fibrillation and ventricular ectopy are recognized complications, particularly in pre-existing structural heart disease

Angiotensin II (Giapreza): The Newest Option

Angiotensin II received FDA approval for vasodilatory shock in 2017 following the ATHOS-3 trial. It acts through AT1 receptors on vascular smooth muscle, independent of both adrenergic and vasopressin pathways. This third independent vasoconstriction mechanism makes it theoretically valuable in patients who have failed the first two lines.

Dosing: Start at 20 ng/kg/min IV; titrate by 15 ng/kg/min every 5–15 minutes to a maximum of 80 ng/kg/min in the first 3 hours, then maximum 40 ng/kg/min. The titration schedule is more complex than most vasopressors; most units have a pharmacy-prepared titration protocol. Know yours before this patient arrives.

Key ATHOS-3 findings relevant to nursing practice:

• Angiotensin II significantly raised MAP in patients unresponsive to norepinephrine plus vasopressin, with 70% of the treatment group reaching MAP target at 3 hours vs. 23% of placebo.
• A pre-specified analysis showed striking mortality benefit in patients with AKI who were on continuous renal replacement therapy (CRRT). CRRT filters remove angiotensin II, creating relative angiotensin II deficiency. If your patient is in refractory shock AND on CRRT, angiotensin II has the most clinical rationale of any second-line agent.
• Thromboembolism risk was higher in the treatment arm. DVT prophylaxis is mandatory when using angiotensin II.

Angiotensin II is extraordinarily expensive. A 2.5 mg vial costs several thousand dollars at most institutions. Formulary access varies widely; confirm pharmacy stock before the emergency.

Methylene Blue: Rescue for Refractory Vasodilation

Methylene blue inhibits nitric oxide synthase and guanylate cyclase, blocking the nitric oxide pathway responsible for pathological vasodilation in septic shock, anaphylactic shock, and post-cardiac surgery vasoplegia. It lacks large RCT support but has a mechanistically coherent and specific role in refractory cases.

Indications where evidence is strongest:

• Anaphylactic shock refractory to epinephrine (strongest evidence base for methylene blue)
• Vasoplegic syndrome after cardiac surgery with cardiopulmonary bypass
• Refractory septic shock as a rescue agent when catecholamines, vasopressin, and angiotensin II have all failed
• Nitric oxide excess from poisoning (nitroprusside toxicity, some antidepressant overdoses)

Dosing: 1–2 mg/kg IV over 15–60 minutes as a loading dose. May be followed by a continuous infusion at 0.25–1 mg/kg/hr if response is seen but not sustained.

Corticosteroids: Addressing Relative Adrenal Insufficiency

Hydrocortisone for septic shock is indicated in patients who remain hemodynamically unstable despite adequate vasopressor therapy—not as a prophylactic or first-line agent. The 2021 Surviving Sepsis Campaign guidelines recommend hydrocortisone 200 mg/day IV in adults with septic shock not responding to norepinephrine at or above 0.25 mcg/kg/min after adequate fluid resuscitation.

The ADRENAL trial (3,800 patients) showed no mortality benefit from hydrocortisone alone but significant faster shock reversal (more vasopressor-free days, faster ICU discharge). The APROCCHSS trial showed mortality benefit with hydrocortisone 200 mg/day plus fludrocortisone 50 mcg daily (via NG tube). Many intensivists now combine both in the sickest refractory shock patients.

Nursing considerations with steroids in shock:

• Hyperglycemia is universal with high-dose steroids. Anticipate and tighten insulin protocol when steroids are added—do not wait for the glucose to spike.
• Watch for steroid-associated myopathy with courses extending beyond 3–5 days at 200–300 mg/day. This contributes to ICU-acquired weakness that prolongs ventilator weaning.
• Do not stop hydrocortisone abruptly after several days of use. Taper over 48–72 hours to prevent adrenal suppression rebound. Many units switch to hydrocortisone 50 mg q6h, then 25 mg q6h, then discontinue.
• Steroids improve vasopressor responsiveness and accelerate weaning, but they do not replace vasopressors. If MAP is improving and vasopressor requirements are trending down, the steroid is working even if absolute numbers are still borderline.

The Clinical Sequence

Monitoring the Triple-Vasopressor Patient

When a patient requires three or more vasopressors, your monitoring workload increases substantially. Parameters to trend every 1–2 hours in true refractory shock:

• Lactate: Rising lactate despite improving MAP and stable hemodynamics suggests worsening tissue perfusion or epinephrine-mediated effect. Confirm with clinical assessment; lactate alone does not drive management decisions. Repeat q2h in refractory shock.
• ScvO2 via central line: Below 65% suggests cardiac output is inadequate relative to demand. Above 80% in shock suggests distributive physiology (typical sepsis) or severely reduced O2 consumption (late, decompensated shock). Use the number in clinical context.
• Urine output: Less than 0.5 mL/kg/hr for 2 or more consecutive hours despite MAP ≥65 is a clinical event requiring escalation. In refractory shock, this signals either inadequate perfusion pressure for that patient's individual autoregulatory threshold, or evolving AKI requiring nephrology involvement.
• Skin perfusion: Mottling score, capillary refill time, skin temperature gradient (core to periphery). These clinical surrogates require your eyes and hands—they are not captured by the monitor. Assess every 2 hours during refractory shock.
• Vasopressor line integrity: All vasopressors must infuse through a confirmed, functioning central line. Norepinephrine and vasopressin extravasation causes tissue necrosis. Verify placement, confirm line is flushing freely, and monitor insertion sites each nursing assessment.

This article is general educational information for licensed clinicians and students, not medical advice or a substitute for your institution's protocols, pharmacy guidance, or a provider's orders. Always follow facility policy and verify doses independently.